Welcome to our dedicated page for CDT Equity SEC filings (Ticker: CDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Conduit Pharmaceuticals Inc's SEC filings reveal the financial structure and operational details of a development-stage biopharmaceutical company that has not yet generated product revenue. The company's 10-K annual reports and 10-Q quarterly filings detail research and development expenditures, partnership agreement structures, patent prosecution costs, and the equity financing mechanisms used to fund operations. For pharmaceutical development companies, these disclosures provide insight into capital runway, partnership economics, and the intellectual property portfolio that represents the company's primary asset base.
Form 8-K filings document material events including partnership announcements, patent approvals, compliance notifications from Nasdaq regarding listing requirements, and corporate governance changes. These current reports often provide the first formal disclosure of significant business developments, making them valuable for tracking the company's progress in establishing partnerships and securing intellectual property rights. The timing and content of 8-K filings can signal important shifts in the company's development trajectory or corporate structure.
Form 4 insider transaction filings track stock purchases and sales by company executives and directors, providing transparency into how management and board members view the company's prospects through their personal investment decisions. For development-stage biopharmaceutical companies, insider transaction patterns can reflect confidence in pipeline progress or reactions to capital requirements and dilution from equity financing activities. These filings also disclose stock-based compensation grants, revealing how the company aligns management incentives with shareholder interests.
Proxy statements on Form DEF 14A detail executive compensation structures, board composition, and governance proposals submitted for shareholder votes. For pharmaceutical development companies, compensation disclosures show how incentive programs tie to development milestones, patent achievements, and partnership execution rather than revenue or earnings metrics typical of commercial-stage companies. Proxy filings also reveal the expertise and industry backgrounds of board members, indicating the strategic guidance available to management.
CDT Equity Inc. filed its quarterly report for September 30, 2025. The company reported a net loss of
Management disclosed “substantial doubt” about the company’s ability to continue as a going concern. The company plans to seek additional financing and noted its remaining at‑the‑market capacity of approximately
Stockholders’ equity improved to
Amendment No. 3 to a Schedule 13D reports that Conduit Pharmaceuticals Inc. granted Dr. Andrew Regan 1,120,000 shares of common stock as director/officer compensation under the company’s Amended and Restated 2023 Stock Incentive Plan, valued at $0.6863 per share (closing Nasdaq price on September 18, 2025). The filing states 9,744,300 shares outstanding and discloses that Dr. Regan now beneficially owns 1,294,993 shares (approximately 13.3%) of the class, including shares held directly and through entities he controls. Corvus, Algo and Manoira ownership details are provided, and the Stock Incentive Plan is incorporated by reference as an exhibit.
On September 19, 2025, CDT Equity Inc. granted Dr. Andrew Regan 1,120,000 shares of common stock under its Amended and Restated 2023 Stock Incentive Plan as compensation for his services as a director and officer. The grant price reported reflects the closing price on September 18, 2025 at $0.6863 per share. After the grant, Dr. Regan directly beneficially owns 1,120,044 shares and also may be deemed to beneficially own additional shares held of record by Manoira Corporation, Corvus Capital Ltd., and Algo Holdings, Inc., entities connected to him by ownership and control.
James Bligh, CFO and Director of CDT Equity Inc. (CDT), was granted 480,000 shares of restricted common stock on 09/19/2025. The restricted shares were granted under the company's Amended and Restated 2023 Stock Incentive Plan and, according to the filing, vest immediately upon grant. The filing states the award had an approximate value of $329,424 based on the issuer's closing share price on 09/18/2025. After the reported transaction the Form 4 shows 480,024 shares beneficially owned by the reporting person in a direct ownership form. The filing is signed by James Bligh on 09/19/2025.
CDT Equity Inc. director Simon Jeremy Fry received equity awards disclosed on Form 4 showing two grants tied to his service. He was granted 35,000 restricted stock units (RSUs) on 08/12/2025 that vested immediately and were valued at approximately $60,900 based on the closing share price that day. At the 2025 annual meeting he was also granted 15,000 stock options with an exercise price of $1.89, exercisable immediately and expiring on 08/05/2035. After these transactions Mr. Fry beneficially owned 36,956 shares of common stock and held options covering 15,000 shares.
Freda C. Lewis-Hall, a director of CDT Equity Inc. (CDT), reported equity awards and holdings. On 08/12/2025 she received 35,000 restricted stock units (RSUs) in exchange for past services; the RSUs vested immediately and were valued at approximately $60,900 based on the 08/12/2025 closing price. The earliest transaction date reported is 08/05/2025, when she was granted 15,000 stock options under the 2023 Stock Incentive Plan at an exercise price of $1.89; those options vested immediately, are exercisable as of 08/05/2025 and expire 08/05/2035. Following the RSU grant, Ms. Lewis-Hall directly beneficially owned 38,466 shares; she also discloses indirect holdings of 1,335 shares held by Intelmed LLC and 344 shares held by her spouse, which she disclaims except to the extent of any pecuniary interest. The Form 4 is signed by Ms. Lewis-Hall on 08/26/2025.
Farley Chele Chiavacci, a director of CDT Equity Inc., received both restricted stock units and stock options as compensation tied to recent corporate actions. She was granted 35,000 restricted stock units on 08/12/2025 that vested immediately and were valued at approximately $60,900 based on the issuer's closing share price that day. Separately, she received options to buy 15,000 shares at an exercise price of $1.89, with the options exercisable immediately and expiring on 08/05/2035. Following these transactions, she directly beneficially owns 37,369 common shares and 15,000 options.
Sarborg Limited reports a passive 4.0% stake in CDT Equity Inc. The filing, an amendment to Schedule 13G, states Sarborg beneficially owns 123,595 shares of CDT Equity Inc. (ticker CDT). The amount reported reflects a 1-for-15 reverse stock split effected by the issuer on May 15, 2025; share totals were adjusted to give effect to that split.
The filing indicates Sarborg has sole voting and dispositive power over all 123,595 shares and that the position was not acquired to influence control of the company. Ownership is based on 3,065,025 shares outstanding as of August 13, 2025, as confirmed by the issuer.
Conduit Pharmaceuticals (CDT) reported cash and cash equivalents of $3.3 million at June 30, 2025, up from $0.6 million at December 31, 2024. For the six months ended June 30, 2025 the company recorded a net loss of $10.8 million (vs. $8.9 million a year earlier) and used $6.5 million in operating cash (vs. $3.9 million). Management states there is substantial doubt about the company’s ability to continue without raising additional equity or debt financing. The filing discloses two reverse stock splits (1-for-100 in January and 1-for-15 in May 2025), outstanding convertible instruments and warrants, and multiple financings and settlements during the period including repayment and extinguishment gains/losses on certain notes. The Board authorized a $1.0 million open repurchase program and the company repurchased 11,713 shares at an average price of $8.85 per share.
FAQ
What is the current stock price of CDT Equity (CDT)?
What is the market cap of CDT Equity (CDT)?
